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Microarray gene expression signatures hold great promise to improve diagnosis and prognosis of disease. However,
current documentation standards of such signatures do not allow for an unambiguous application to study-external
patients. This hinders independent evaluation, effectively delaying the use of signatures in clinical practice. Data from
eight publicly available clinical microarray studies were analyzed and the consistency of study-internal with study-
external diagnoses was evaluated. Study-external classifications were based on documented information only.
Documenting a signature is conceptually different from reporting a list of genes. We show that even the exact
quantitative specification of a classification rule alone does not define a signature unambiguously. We found that
discrepancy between study-internal and study-external diagnoses can be as frequent as 30% (worst case) and 18%
(median). By using the proposed documentation by value strategy, which documents quantitative preprocessing
information, the median discrepancy was reduced to 1%. The process of evaluating microarray gene expression
diagnostic signatures and bringing them to clinical practice can be substantially improved and made more reliable by
better documentation of the signatures.
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Introduction
It has been shown that microarray based gene expression
signatures have the potential to be powerful tools for patient
stratiﬁcation, diagnosis of disease, prognosis of survival,
assessment of risk group and selection of treatment [1–3].
These signatures are computational rules for deriving a
diagnosis from a patient’s expression proﬁle. Micorarray
based molecular diagnosis constitutes a promising approach,
but so far it has been difﬁcult to exploit its potential. Before
gene expression signatures can impact clinical practice, they
need to be communicated to other health care centers with
data for external evaluation [2], and ultimately to practi-
tioners for use in clinical routine. This requires unambiguous
documentation of the signature.
We believe documentation does not receive sufﬁcient
attention. For instance, it has been observed that the
reconstruction of published signatures can require an expert
re-analysis of the study [4] or may not be possible at all [5].
Documenting a signature is conceptually different from
reporting a list of genes contributing to the classiﬁcation
rule, since the latter does not determine how an external
patient should be diagnosed. Moreover, we show that even the
exact quantitative speciﬁcation of the classiﬁcation rule does
not constitute a ready-to-use signature. In addition, a
procedure transforming raw external expression data to the
signature-speciﬁc scale has to be provided.
Based on eight clinical microarray studies [6–13] we show
that common documentation standards have the following
shortcoming: When using the documented information only,
a study-external patient might receive a diagnosis different
from the one he would have received as part of the original
study. To address the problem, we propose guidelines and
methodology for building and documenting signatures
unambiguously. We demonstrate that our approach reduces
ambiguity of diagnoses to a minimum.
Results
Ambiguity of Diagnosis
Before we start with a systematic analysis of the signature
documentation problem, we illustrate it in the context of the
breast cancer study of Huang et al. [9]. This study includes
expression proﬁles from 89 breast cancer patients. The
majority (34) had no recurrence of disease, 18 suffered from
a relapse and for the rest no data about recurrence is
available. We preprocessed the entire study data using the
rma protocol (see Methods), and derived a prognostic
signature using a subset of the data (training set). Patient
00291471 was not part of the training set. When applying the
signature, this patient was predicted to be relapse free. Next,
we classiﬁed patient 00291471 a second time, this time as a
study-external patient from another health care center.
Consequently, the expression proﬁle was preprocessed
independently from the study data but using the same
preprocessing protocol (rma). Again, we applied the prog-
nostic signature, and this time the patient was predicted to
relapse. The reason for this inconsistency is that any
quantitative speciﬁcation of the classiﬁcation rule critically
depends on the scale of the preprocessed data. The scale, in
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process, which is different in an internal and an external
analysis.
Documentation Strategies
We studied the signature documentation problem more
systematically on eight clinical microarray studies [6–13]
involving different cancer types and representing diagnostic
as well as prognostic classiﬁcation problems. Table 1 gives an
overview. We compared two different documentation strat-
egies:
Documentation by reference. The signature is documented
by a quantitative classiﬁcation rule and by referencing the
underlying preprocessing protocol. This includes the book-
keeping of user-adjustable parameters, such as the target
scale for the standard Affymetrix protocol (mas). External
cases are preprocessed by running the speciﬁed procedure
exclusively on the new data.
Documentation by value. The signature is documented by a
quantitative classiﬁcation rule and by supplying a set of
parameters (values) determined by the ﬁtted vsn and rma
preprocessing procedures (see Methods). These parameters
depend on the data that was preprocessed and determine its
scale. External cases are scaled by using the corresponding
add-on preprocessing routines (see Methods).
Documentation by reference does not include properties
of the study data. A comparable scale is assumed to be
generated automatically, given the exact details of the
preprocessing routine. In contrast, documentation by value
communicates the scale implied by the study data explicitly.
Data normalized by rma was documented using both
strategies. In case of vsn, normalized data was documented
by value only. The reason is that documentation by reference
requires applying the preprocessing protocol to a single
array. In the case of vsn, the normalization step requires more
than one array, so this is not possible. On the other hand,
documentation by value works well in this setting. Finally, for
the Affymetrix Microarray Analysis Suite the two strategies
coincide, since arrays are normalized independently of each
other.
Consistency of Diagnosis
We calculated consistency and kappa index as described in
the Methods Section. To that end, we repeatedly split each
dataset into an internal set (of size 20, 30 and 40) to derive the
signature and an external set for validation (using docu-
mented information only). This mimics the process of
communicating signatures between health care centers. The
validation results were compared to a reference diagnosis and
the fraction of agreement is reported as consistency. This
procedure requires the encoding (documentation) of signa-
ture information and its subsequent decoding for use on
external data.
The main results are summarized in Table 2, the complete
details can be found in supplemental Figures S1 to S8. First,
we observed in the study by Beer et al. [6] that documentation
by reference can lead to discrepancies between external and
internal diagnosis being as frequent as 30%. The median
consistency across all studies using documentation by
reference was 82%, corresponding to a median discrepancy
of diagnoses as high as 18%. This demonstrates the existence
and importance of the documentation problem. External
researchers will generally not obtain the same diagnoses as
the investigators of the original study. More importantly, we
observed that the documentation strategy matters: Docu-
menting signatures by value leads to substantially more
consistent results than documentation by reference. We
observed the biggest effect for the prognostic study by Beer
et al., where consistency improved from 70% to 99%. This
corresponds to a consistency gain between 27% and 31%
(95% CI).
The smallest consistency gain (between 3% and 4%, 95%
CI) was observed for the diagnostic study of Willenbrock et al.
[13], which poses the easiest classiﬁcation problem. The
median minimal gain in consistency (97.5 % CI) obtained
from documenting signatures by value was 15%. On most
datasets consistency of rma and vsn preprocessing were
comparable; the differences were small. Exceptions are the
datasets of Huang et al. [9] and Ross et al. [11], where
consistencies obtained with rma were larger. Overall,
signatures documented by value displayed high consistency,
most of them larger than 98%. Documentation by reference
was found to be signiﬁcantly less consistent (about 15%
median consistency loss). Surprisingly, we see no big effect of
the size of the internal set on the observed consistency
(Supplemental Figures S1-S8). Also, the two learning algo-
rithms (SVM and shrunken centroids, see Methods) seem to
perform comparable with respect to consistency (Figures S1-
S8). Note that for data normalized with the Affymetrix
Microarray Analysis Suite the consistency problem does not
exist. Since arrays are normalized independently of each
other, one is guaranteed to receive 100% consistency.
Discussion
To the best of our knowledge, this is the ﬁrst study
investigating the problem of documenting diagnostic ex-
pression signatures. We were able to demonstrate that
common documentation standards are insufﬁcient for
unambiguously determining diagnosis. Moreover, we have
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Author Summary
It has been shown that microarray based gene expression signatures
have the potential to be powerful tools for patient stratification,
diagnosis of disease, prognosis of survival, assessment of risk group,
and selection of treatment. However, documentation standards in
current publications do not allow for a signature’s unambiguous
application to study-external patients. This hinders independent
evaluation, effectively delaying the use of signatures in clinical
practice. Based on eight clinical microarray studies, we show that
common documentation standards have the following shortcoming:
when using the documented information only, the same patient
might receive a diagnosis different from the one he would have
received in the original study. To address the problem, we derive a
documentation protocol that reduces the ambiguity of diagnoses to
a minimum. The resulting gain in consistency of study-internal
versus study-external diagnosis is validated by statistical resampling
analysis: using the proposed documentation by value strategy, the
median inconsistency dropped from 18% to 1%. Software imple-
menting the proposed method, as well as practical guidelines for
using it, are provided. We conclude that the process of evaluating
microarray gene expression diagnostic signatures and bringing
them to clinical practice can be substantially improved and made
more reliable by better documentation.
Documentation of Expression Signaturesshown that the consistency of diagnostic signatures can be
substantially improved by documenting data-dependent
preprocessing information. To do so, we have proposed the
documentation by value strategy.
We observed a trade-off between the reported perform-
ance of preprocessing protocols and the effort required for
documenting them [14,15]. While it is known that preprocess-
ing schemes that share information across arrays enhance
precision and accuracy of estimated expression differences,
improved normalization performance comes at a price: The
already normalized expression values for a ﬁxed microarray
change when additional arrays are added to the study. This is
a problem for applying a signature to external data; the
original data needs to be included in the normalization of
external arrays. The re-normalization of the complete dataset
changes the original expression values, affecting the signature
and the molecular diagnosis of patients in the original study.
To circumvent this problem, we have altered the widely used
preprocessing methods rma [16] and vsn [17] to provide an
add-on mode. This allows one to ﬁrst process a core dataset,
and then to add data from additional arrays without changing
the normalized core data.
As a summary of our ﬁndings we propose the following
guidelines for deriving and documenting a diagnostic gene
expression signature:
Preprocessing
Preprocess the data using a protocol that allows for later
inclusion of arrays without changing the original expression
values. For example, this can be done preprocessing arrays
independently of each other, or by making use of the software
we provide.
Building the Classification Rule
Derive a classiﬁcation rule using software that provides a
complete quantitative speciﬁcation of the signature for
documentation purposes. For example, this can be the
nearest shrunken centroid procedure [18] we employed.
Documentation by Value
Document the full quantitative speciﬁcation of the
classiﬁcation rule. In addition, document preprocessing by
including aggregate data-dependent information. For exam-
ple, this can be done with the software we provide. Ideally,
make both parts available as an integrated open source
computer program that can readily be used to diagnose new
patients.
Diagnosing an External Patient
Bring the raw data to a signature consistent scale. For
example by using our software. Apply the documented
classiﬁcation rule to diagnose the new patient.
These guidelines suggest methods we have found to work
well in practice, but we do not claim them to be optimal in
any sense. Given the heterogeneity of clinical data as well as
the diversity of array platforms, it can safely be assumed that
there is data where other methods are more appropriate.
However, we believe that in these situations the documenta-
tion problem still exists, and a similar documentation by
value strategy should be developed for the methodology in
use.
In our simulation setup, the data we call external are
actually arrays from the same study. With real external data,
additional problems occur. It has been shown that even when
using the same technology and experimental protocols, the
resulting data for the same tissue sample varies between
different health care centers [15,19]. Also, different centers
might not employ the same deﬁnitions of outcomes and/or
diagnoses. While this effect is not directly linked to
documentation, we believe that the beneﬁts of documenting
signatures by value are enhanced in situations where external
and internal data are more heterogeneous.
Documentation of signatures is signiﬁcantly easier for
preprocessing methods treating arrays independently of each
other, as is the case for the Affymetrix Microarray Suite.
However, preprocessing protocols sharing information across
different arrays are commonly used as they can provide
increased accuracy [15]. Overall, methods like mas present a
viable alternative to more advanced procedures whenever
consistency is of prime importance, as it is the case in clinical
microarray studies. In our study we did not ﬁnd strong
evidence favoring one approach over the other.
While microarray based diagnostic signatures hold great
promise to improve diagnosis and prognosis of disease,
evaluation of a signature’s predictive performance is difﬁcult
and subject to current research and argument [4,19–23]. It is
important to prove that a signature holds independent
complementary information to existing prognostic markers.
While sharing candidate signatures within the research
community can accelerate the process of evaluation, this
Table 1. Summary of Microarray Studies
Study Disease Problem Number of Cases Accuracy Documentation Gain
Beer [6] Adenocarcinoma Prognostic 84 72% (71%) 29%
Bhattacharjee [7] Adenocarcinoma Prognostic 125 63% (62%) 18%
Bild [8] Ovarian cancer Prognostic 133 69% (54%) 16%
Huang [9] Breast cancer Prognostic 52 81% (65%) 12%
Pomeroy [10] Medullablastoma Prognostic 60 67% (65%) 19%
Ross [11] Childhood ALL Risk Group 87 81% (81%) 19%
Shipp [12] DLBCL Prognostic 58 64% (62%) 11%
Willenbrock [13] Childhood ALL Diagnostic 45 100% (58%) 4%
Overview of the eight studies used to investigate the signature documentation problem. As accuracy we report a 10-fold cross validation estimate, averaged over 100 different random
partitionings. In parentheses we report the prevalence. Documentation gain denotes the increase in consistency when using documentation by value instead of documentation by
reference (see Results).
doi:10.1371/journal.pcbi.0040022.t001
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Documentation of Expression Signaturesdoes not allow for any ambiguity of signatures. We believe
that our documentation by value strategy removes this
obstacle and greatly facilitates signature evaluation. The
additional effort required for documentation by value is
small. There are certainly several ways to implement
documentation by value, and we provide suggestions for
two preprocessing schemes. Overall, we found that the
consistency of diagnoses based on gene expression diagnostic
signatures critically depends on the documentation of the
signature. Optimal consistency was obtained by using the
proposed documentation by value strategy.
Methods
Data sources. We studied the signature documentation problem on
eight clinical microarray studies [6–13], involving different disease
types and representing diagnostic as well as prognostic classiﬁcation
problems. See Table 1 for an overview.
Preprocessing. Raw microarray data is subject to noise. There is
variation in the data that is not due to biological signal, but rather to
measurement error or experimental artifacts. Prior to data analysis it
is therefore common practice to perform data preprocessing.
Preprocessing procedures depend on the microarray technology in
use. We focused on Affymetrix GeneChip technology, where data
preprocessing commonly includes three steps: Background correc-
tion, normalization and probeset summary. We focus on three of the
most widely used protocols: Standard preprocessing as provided by
the Affymetrix Microarray Analysis Suite Version 5 (mas) [24], a
procedure called ’’robust multi-chip average’’ (rma) [16], and a
variance stabilizing method (vsn) [17]. For vsn and rma we provide an
’’add-on’’ mode. This mode enables one to ﬁrst process a core dataset,
and then to add data from additional arrays without changing the
normalized core data.
Learning algorithms. In order to achieve comparable results across
studies, we re-learned classiﬁcation rules using the same two learning
algorithms for all datasets. We chose a nearest shrunken centroid
classiﬁer (pam) [18] that was shown to perform well in recent
comparisons of classiﬁcation algorithms [20,25]. Additionally we used
support vector machines (SVMs) [26] with a linear kernel. In the case
of pam, classiﬁcation rules were documented by gene-speciﬁc weights
and class-speciﬁc shrunken centroids. For the SVMs gene speciﬁc
scaling factors, the support vectors and the offset were documented.
All these parameters depend on the scale of the preprocessed data.
Consistency. Consistency of a signature was assessed through re-
learning, using 1000 different random subsets of the study data (sub-
sampling), and then analyzing the diagnoses of patients across all sub-
sampling runs. We randomly split each of the eight datasets into two
parts, which we call the internal and the external set. The size of the
internal sets was ﬁxed to 20, 30 and 40 arrays for all datasets. For a
given preprocessing and documentation strategy (see Results), we ﬁrst
derived and documented a signature using the internal set. Then we
applied this signature to a random sample of the external set,
exclusively using the information documented beforehand. This
mimics the process of communicating signatures between health care
centers.
For evaluation of performance we determined the diagnosis a
patient would have received if analyzed in the context of the original
study (reference diagnosis). To this end, we concatenated each
external case with the (say N ) internal arrays, renormalized this
complete dataset of N þ 1 cases and applied the signature to the
external case. The result constitutes the reference diagnosis for this
patient. Then we compared all prior diagnoses from the sub-sampling
runs to the reference. The fraction of matching diagnoses was
reported as a consistency index. A consistency of one corresponds to
the situation where all diagnoses were identical to the reference. A
consistency of zero implies that all diagnoses were different from the
reference. In addition we report the kappa index [27], a statistical
measure to assess inter-rater reliability.
Statistical analysis. All conﬁdence intervals were calculated
assuming Bernoulli models for class predictions. In the case of
conﬁdence intervals for consistency gains, an additional convolution
of estimated Binomial densities was carried out. More details can be
found in supplemental material.
Signature documentation. In the core of this paper lies the
documentation by value strategy for documenting diagnostic
signatures: In addition to the parameters describing a classiﬁcation
rule, documentation by value also keeps track of the normalization
dependent scale that is underlying the signature. This scale does not
only depend on the preprocessing strategy, but also on the original
data. In the following, we demonstrate how to document the scale for
two preprocessing methods, rma and vsn.
Documenting quantile normalization. For rma, background cor-
rection is performed on an array-by-array basis. The subsequent
normalization step can be documented as follows. Assume we have p
probes and n arrays. Let X be the p3n background corrected probe-
level expression matrix on log scale. Let p be the permutation sorting
the columns of X and p
 1 its inverse. Then the quantile normalized
[28] version of ~ X of X is deﬁned as:
~ X ¼ p 1ðpðXÞ1Þ;
Table 2. Documentation by Value Increases Consistency
Dataset rma (ref) rma (val) vsn (val) Gain
Beer [6] Consistency 70 (68, 73) 99 (98, 99) 99 (98, 99) 29 (27, 31)
Kappa index 40 (34, 46) 98 (96, 99) 97 (96, 99)
Bhattaharjee [7] Consistency 81 (79, 83) 99 (98, 99) 98 (98, 99) 18 (16, 20)
Kappa index 62 (56, 67) 98 (96, 99) 97 (95, 98)
Bild [8] Consistency 83 (81, 85) 99 (99, 100) 98 (98, 99) 16 (14, 16)
Kappa index 67 (62, 71) 98 (97, 100) 97 (95, 98)
Huang [9] Consistency 87 (86, 89) 99 (99, 100) 89 (87, 90) 12 (11, 13)
Kappa index 74 (70, 78) 99 (98, 100) 77 (73, 81)
Pomeroy [10] Consistency 80 (78, 82) 99 (98, 99) 96 (95, 97) 19 (17, 20)
Kappa index 60 (55, 65) 97 (96, 99) 93 (90, 95)
Ross [11] Consistency 79 (77, 82) 98 (98, 99) 94 (93, 96) 19 (17, 21)
Kappa index 59 (53, 64) 97 (95, 98) 88 (85, 92)
Shipp [12] Consistency 88 (86, 90) 99 (99, 100) 98 (98, 99) 11 (10, 13)
Kappa index 75 (71, 80) 99 (97, 100) 98 (96, 99)
Willenbrock [13] Consistency 96 (95, 97) 99 (99, 100) 100 (99, 100) 4 (3, 4)
Kappa index 92 (89, 95) 99 (98, 100) 99 (99, 100)
Each row contains consistency results for one of the eight clinical microarray studies. For the preprocessing schemes rma and vsn, we report consistency and kappa indices (see Methods)
for signatures documented by reference (rma only [ref]) and signatures documented by value (val). The last column displays the gain in consistency when using documentation by value
(rma only). Confidence intervals are given in parentheses (95%). The size of the internal dataset was 40 arrays, except for the studies of Huang et al. [9] and Ross et al. [11], where the study
size restricted us to 30 arrays. Documentation by value significantly increases consistency in all studies. rma, robust multi-chip average; vsn, variance stabilizing method.
doi:10.1371/journal.pcbi.0040022.t002
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Documentation of Expression Signatureswhere 1 is a n3p matrix with all elements equal to 1/n. Let ^ l be equal
to the ﬁrst (and therefore any) column of p(X)1. Then ^ l is the vector
of (identical) quantiles of each normalized array. To bring an external
array to this scale, let x 2 R
p be its raw probe level expression values.
If px is the permutation sorting the entries of x, a scale-consistent
version of x is given by
~ x ¼ p 1
x ð^ lÞ:
The normalized array ~ x is consistent with the scale of the other
arrays as it has the same quantiles. Since px depends on the sorting of
the entries of x only, we do not need to worry about a global
background correction. That is, up to probeset summary, rma can be
documented by keeping track of ^ l.
Documenting the variance stabilizing transformation. In the case
of vsn, the raw probe-level expression matrix X is background
corrected and normalized simultaneously. Huber et al. [17] relate
random variables Xki (k¼1...p and i¼1...n) to the true abundance
lk of probe k on array i, given probe k is not differentially expressed:
arsinhðai þ XkibiÞ¼hðXki;ai;biÞ¼lk þ eki;eki ;Nð0;c2Þ: ð1Þ
The parameters ai 2 RR, bi 2 Rþand c 2 Rþare estimated from the
data.
Assume vsn normalized core data is at hand. For n arrays we have
normalized expression values f^ hðxkiÞ¼hðxki;^ ai;^ biÞg with i¼1...n and
k¼1... p, and corresponding parameter estimates f^ ai;^ big. Also, a set
K of not differentially expressed genes has been identiﬁed. This
implies estimates ^ l ¼f ^ lkg for each gene k e K and an estimate of the
variance of the residuals in (1):
^ lk ¼
1
n
X n
i¼1
^ hiðxkiÞ and ^ c2 ¼
1
njKj
X
k2K
X n
i¼1
ð^ hðxkiÞ ^ lkÞ2:
We want to transform an external sample x
e to the scale
determined by the n core arrays. By employing the same model as
for the core data (Equation (1)) and plugging in the estimates, we get
maximum likelihood estimators for the parameters a
e and b
e:
ðae;beÞ¼argmin
ða;bÞ
(
X
k2K
ðhðxki;a;bÞ lkiÞ
2
2c2  
X
k2K
logð@xkhðxe
k;a;bÞÞ
)
which can be calculated numerically. These estimators are completely
determined by ^ l,^ c2 and measurement values from the external array.
Theydeﬁnethevariancestabilizingtransformationhðxe
kÞ¼hðae þ bexe
kÞ
bringingx
etothesamescaleasthecoredata.Therefore,uptoprobeset
summary, vsn preprocessing is fully documented by ^ l and ^ c2.
Documenting an additive model for probeset summary. Let X
(k) be
the submatrix of normalized expression values indexed by the probes
belonging to probe set k (across all arrays). Let there be l probes in
probeset k. Then an additive model assumes
X
ðkÞ
ij ¼ p
ðkÞ
i þ g
ðkÞ
i þ eij;
where p
ðkÞ
i , i ¼ 1...l, is a probe speciﬁc effect and g
ðkÞ
j , j ¼ 1...n,
represents the abundance of mRNA of gene k on array j. The
parameters ^ p
ðkÞ ¼f ^ p
ðkÞ
i g and ^ gðkÞ ¼f ^ g
ðkÞ
j g can e.g. be estimated by the
median polish procedure [29]. Denote by x
e a (suitably normalized)
external array. Let x
e,(k) denote the values for probeset k. Then median
(x
e,(k)  ^ p
ðkÞ) denotes a consistent estimate of the expression of gene k.
That is, the additive model is fully documented keeping track of the
probe effects ^ p
ðkÞ for all probesets on the array.
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